Everstone-backed firm CPC Diagnostics launches Covid-19 antibody tests

Depending on the analyser model, a lab can report up to 2,000 results a day on a single instrument, with flexibility for facilities to add further modules to ramp up output substantially

CPC Diagnostics (CPC), a portfolio company of Everstone backed healthcare platform Everlife Holdings Pte, has launched SARS COV-2 IgM and SARS COV-2 IgG tests in India. Both are European-approved antibody tests and the first of their kind to be cleared by the Indian Council of Medical Research (ICMR) as well, the company said. 

The tests, developed by Shenzhen-based YHLO Biotech Co Ltd, run on the fully-automated analysers iFlash 1800/3000, offering sensitivity of 97.3 per cent and 86.1 per cent for IgG and IgM with specificity of 96.3 per cent and 99.2 per cent respectively, said the company.

ALSO READ: